Trial Profile

A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Dexamethasone; Dexamethasone; Fludarabine
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Adverse reactions
Acronyms ZUMA-24
Sponsors Gilead Sciences; Kite Pharma

14 Jun 2024 According to a Gilead Sciences media release, data from this trial presented at 2024 European Hematology Association (EHA) Annual Congress
14 Jun 2024 Results published in the Gilead Sciences Media Release
14 May 2024 According to a Gilead Sciences media release, data from this trial will be presented at 2024 European Hematology Association (EHA) Annual Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com